MindMed to Participate in H.C. Wainwright Global Investment Conference USA - English USA - English USA - English

MindMed to Participate in H.C. Wainwright Global Investment Conference USA – English USA – English USA – English

Post published:September 7, 2022
Post category:Press Release

NEW YORK, Sept. 7, 2022 /PRNewswire/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that it will participate virtually at the H.C. Wainwright 24th Annual Global Investment Conference, and its presentation will be available beginning at 7:00 a.m. ET on September 12, 2022.

For details or to register to attend please visit https://hcwevents.com/annualconference/. A replay of the webcast will be available in the “News & Media” section of MindMed’s website.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel products to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative drug candidates, with and without acute perceptual effects, targeting the serotonin, dopamine and acetylcholine systems.

MindMed trades on NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

For Media: [email protected]

For Investors: [email protected]

SOURCE Mind Medicine (MindMed) Inc.

Source link

Tags: MindMedicine

Leave a Reply Cancel reply

Insights from the European Medicines Agency’s Psychedelics Workshop: A Pα+ DispatchApril 23, 2024
Last week, the EMA hosted a meeting in Amsterdam, “Multi-stakeholder workshop on psychedelics - Towards an EU regulatory framework”. In this Pα+ Dispatch, Josh explores some of the key themes discussed at the workshop: from regulatory remits and rescheduling through to disentangling pharmacotherapy from psychotherapy, standardisation and its discontents, blinding, and much more.
Pα+ Psychedelic Bulletin #161: Numinus Shifts Focus to US; Algernon Makes DMT for Stroke Lead Asset; atai Pivots to IV IbogaineApril 17, 2024
Numinus’ Shifting Focus Toward U.S. Market Revealed via “Unauthorized Disclosure” • Algernon Pharmaceuticals Makes DMT Stroke Research Program Its Lead Asset • atai Pivots to IV Formulation of Ibogaine • Seaport Therapeutics Launches with $100m Series A, Pipeline Includes ‘Prodrug of a Non-Hallucinogenic Neuroplastogen’ • and more...
Developing Esketamine (Spravato) and Lessons for Psychedelic Drug Developers with Jaskaran SinghApril 12, 2024
Josh Hardman sits down with Jaskaran (‘Jaz’) Singh, who spearheaded the development of esketamine for treatment-resistant depression, now marketed as Spravato. We discuss how Singh’s early work assessing ketamine’s antidepressant effects at the National Institute of Mental Health (NIMH) encouraged him to move into industry; how his team decided to pursue esketamine; lessons learned that might be relevant for psychedelic drug developers; and his broader outlook on the field.
Natural Medicine Advisory Bulletin 10.1: Legislative UpdateApril 9, 2024
Vicente LLP reviews Senate Bill 24-198, the first legislative since the passing of SB-23-290 in 2023, which implemented the Natural Medicine Health Act.
MindMed’s ‘Total Elimination’ of Psychotherapy in LSD Study Stokes Debate Around Its Role in Psychedelic TherapiesApril 5, 2024
In March, MindMed scored an FDA Breakthrough Therapy Designation for its LSD-D-tartrate candidate (MM120) for generalised anxiety disorder (GAD). Here, Josh takes a closer look at the company's claim to have ‘eliminated’ psychotherapy from its Phase 2b study of MM120 and explores how a ‘Spravato-isation’ of psychedelic therapies is stoking broader debates around the contribution of psychotherapy in psychedelic therapies or ‘treatments’.